Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sanofi-Aventis Zimulti (correction)

Executive Summary

Zimulti (rimonabant) is a CB-1 receptor antagonist; a recent article in "The Pink Sheet" mischaracterized the product. Rimonabant is "approvable" at FDA for obesity and "not approvable" for smoking cessation (1"The Pink Sheet" May 7, 2007, p. 25)...

You may also be interested in...



Acomplia’s Large European Cash Market Not Affecting Dropout Rate – Sanofi

A substantial portion of European patients purchasing Sanofi-Aventis' Acomplia pay entirely out-of-pocket for the obesity drug

Paxlovid, Molnupiravir Access Threatened By ‘Dismal' Pharmacy Dispensing Fees, CMS Told

Pharmacy organization urges the Centers for Medicare and Medicaid Services to recommend a dispensing fee commensurate with the effort involved in filling scripts for the drugs.

Califf Confident Public Trust In US FDA Will Be Rebuilt

Commissioner nominee strikes an optimistic note as former FDA heads raise concerns about the decrease in agency credibility during the pandemic.

UsernamePublicRestriction

Register

PS048366

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel